Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Marijuana Testing topic
No spam. Unsubscribe anytime.
Committee hears calls for tighter testing oversight and coordinated response to unregulated intoxicants
Summary
Lawmakers and health officials discussed a medical‑marijuana contamination case, House Bill 33 (testing reforms), and a broader spike in unregulated intoxicating hemp, synthetics and kratom; officials emphasized surveillance, education and interagency review and said a hemp loophole closure is scheduled for this fall.
Members used the hearing to press the Department of Health on lab oversight for medical marijuana and the state's response to a growing market of unregulated intoxicating products.
Chairman Frankel cited a published case in which researchers used whole‑genome sequencing to link a fatal cryptococcal infection to contaminated medical‑marijuana purchased at a licensed dispensary, and asked what statutory or regulatory powers the Department needs to prevent similar tragedies.
"We want to make sure that they're doing their job and that they're doing it well," Secretary Bogan said, noting concerns nationwide about THC inflation and inconsistent testing and adding that the department is open to discussing statutory and regulatory options. The chair noted House Bill 33, which has passed the House and is pending in the Senate, as one legislative vehicle that could strengthen testing oversight.
Members also raised a broader category of unregulated intoxicating products — synthetic opioids, synthetic cannabinoids, intoxicating hemp derivatives and kratom — that are often sold in convenience stores and not covered by current testing or labeling rules. Secretary Bogan said the Department's role centers on surveillance and education and that the administration convened an interagency substance‑use response team to study these products and possible regulatory responses; Dr. Davis Jones said the committee has been examining products for 6–8 weeks.
Officials cautioned that some hemp‑related rule changes (described as closing a "hemp loophole") do not go into effect until this fall and that many other products remain unregulated, requiring ongoing interagency coordination, public education and potential statutory remedies.
No votes or final actions were taken; the department said it welcomes further legislative collaboration on testing standards and public‑education strategies.
